Ikarian Capital’s United Therapeutics UTHR Stock Holding History

Ikarian Capital’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-40,000	Closed	-$9.43M	–	158
2022 Q2	$9.43M	Buy	+40,000	New	+$8.13M	1.72%	17

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AssetMark Inc Concord, California $49B AUM 17.78% 1-Year Est. Return

Ikarian Capital's UTHR Position: Q3 2022 in Review

Ikarian Capital sold out of United Therapeutics (UTHR) in Q3 2022, closing a stake of 40,000 shares — an estimated $9.43M sold.

Ikarian Capital first reported a position in UTHR in Q2 2022 and held it in 1 quarter. The position peaked at $9.43M in Q2 2022. 461 funds tracked by Wall St. Rank hold UTHR as of Q3 2022.

Ikarian Capital reported no remaining United Therapeutics position as of Q3 2022 after selling out during the quarter.
Ikarian Capital sold 40,000 United Therapeutics shares in Q3 2022, an estimated $9.43M.
Ikarian Capital first reported a position in United Therapeutics in Q2 2022 and held it in 1 quarter.
Ikarian Capital's United Therapeutics position peaked at $9.43M in Q2 2022.
461 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2022.

Based on Ikarian Capital's 13F filing for Q3 2022, filed 14 Nov 2022.